Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Funda Meric-Bernstam
841  Ergebnisse:
Personensuche X
?
1

First-In-Human Phase I Study of Tinengotinib (TT-00420), a ..:

Piha-Paul, Sarina A ; Xu, Binghe ; Dumbrava, Ecaterina E...
The Oncologist.  29 (2024)  4 - p. e514-e525 , 2024
Link: https://doi.org/10.1093/..
 
?
2

Safety Profile and Adverse Event Management for Futibatinib..:

Meric-Bernstam, Funda ; Hollebecque, Antoine ; Furuse, Junji...
Clinical Cancer Research.  30 (2024)  8 - p. 1466-1477 , 2024
Link: https://doi.org/10.1158/..
 
?
3

Trastuzumab deruxtecan in patients with solid tumours harbo..:

Li, Bob T ; Meric-Bernstam, Funda ; Bardia, Aditya...
The Lancet Oncology.  25 (2024)  6 - p. 707-719 , 2024
Link: https://doi.org/10.1016/..
 
?
4

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-can..:

Nelson, Blessie Elizabeth ; Roszik, Jason ; Ahmed, Jibran...
Molecular Cancer.  23 (2024)  1 - p. , 2024
Link: https://doi.org/10.1186/..
 
?
5

ASO Visual Abstract: Defining the Biology of Estrogen Recep..:

Higgins, Tessa ; Kantor, Olga ; Harrison, Beth...
Annals of Surgical Oncology.  31 (2024)  4 - p. 2284-2285 , 2024
Link: https://doi.org/10.1245/..
 
?
6

Clinical management, monitoring, and prophylaxis of adverse..:

Heist, Rebecca S. ; Sands, Jacob ; Bardia, Aditya...
Cancer Treatment Reviews.  125 (2024)  - p. 102720 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Var..:

Pilié, Patrick G. ; Giuliani, Virginia ; Wang, Wei-Lien...
Clinical Cancer Research.  30 (2024)  10 - p. 2121-2139 , 2024
Link: https://doi.org/10.1158/..
 
?
8

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TA..:

Subbiah, Vivek ; Coleman, Niamh ; Piha-Paul, Sarina A....
Cancer Research Communications.  4 (2024)  2 - p. 378-387 , 2024
Link: https://doi.org/10.1158/..
 
?
9

Adaptive Darwinian off-target resistance mechanisms to sele..:

Subbiah, Vivek ; Gouda, Mohamed A. ; Iorgulescu, J. Bryan...
npj Precision Oncology.  8 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
10

Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors:

Nelson, Blessie Elizabeth ; Meric-Bernstam, Funda
Annual Review of Medicine.  75 (2024)  1 - p. 31-48 , 2024
Link: https://doi.org/10.1146/..
 
?
11

Assessment of Patient-Derived Xenograft Growth and Antitumo..:

Meric-Bernstam, Funda ; Lloyd, Michael W. ; Koc, Soner...
Molecular Cancer Therapeutics.  23 (2024)  7 - p. 924-938 , 2024
Link: https://doi.org/10.1158/..
 
?
12

Limited Independent Follow-Up with Germline Testing of Vari..:

Nowlen, Carol J. ; Daniels, Molly ; Uzunparmak, Burak...
Journal of Immunotherapy and Precision Oncology.  7 (2024)  1 - p. 7-17 , 2024
Link: https://doi.org/10.36401..
 
?
13

Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Za..:

DiPeri, Timothy P. ; Evans, Kurt W. ; Wang, Bailiang...
Cancer Discovery.  14 (2024)  5 - p. 828-845 , 2024
Link: https://doi.org/10.1158/..
 
?
14

Estrogen Receptor Mutations as Novel Targets for Immunother..:

Goldberg, Jonathan ; Qiao, Na ; Guerriero, Jennifer L....
Cancer Research Communications.  , 2024
Link: https://doi.org/10.1158/..
 
?
15

Plain language summary of the FOENIX-CCA2 study: futibatini..:

Goyal, Lipika ; Meric-Bernstam, Funda ; Hollebecque, Antoine...
Future Oncology.  , 2024
Link: https://doi.org/10.1080/..
 
1-15